Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190208 | 0.88 | MEN1 (0.35) | NPSR1MEN1KMT2AMAPT | |
| SCHEMBL3830372 | 0.86 | NPSR1 (0.32) | NPSR1MEN1KMT2A | |
| SCHEMBL1088376 | 0.85 | DGAT1 (0.36) | — | |
| SCHEMBL17008619 | 0.80 | NPSR1 (0.32) | NPSR1MEN1KMT2A | |
| SCHEMBL21803044 | 0.79 | MEN1 (0.38) | NPSR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL11803523 | 0.77 | NPSR1 (0.35) | NPSR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL3923179 | 0.75 | NPSR1 (0.34) | NPSR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL8349556 | 0.75 | LMNA (0.47) | NPSR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL225044 | 0.75 | NPSR1 (0.46) | NPSR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL12462298 | 0.75 | NPSR1 (0.46) | NPSR1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106893746-A | Biological catalysis synthesize the method for 3- cyclopentene -1,1- dioctyl phthalate | 常熟浸大科技有限公司 | 2017-06-27 | — | — | CN | claimed |
| CN-119552102-A | Synthesis method of dialkyl selenoether compound | 西安交通大学 | 2025-03-04 | — | — | CN | disclosed |
| US-12023661-B2 | Nitrogen heterocyclic carbene ligands and ruthenium catalysts thereof, preparation method therefor and application thereof | Paimai New Materials (chengdu) Co., Ltd. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12023661-B2 | Nitrogen heterocyclic carbene ligands and ruthenium catalysts thereof, preparation method therefor and application thereof | Paimai New Materials (chengdu) Co., Ltd. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20220161246-A1 | NITROGEN HETEROCYCLIC CARBENE LIGANDS AND RUTHENIUM CATALYSTS THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Paimai New Materials (chengdu) Co., Ltd. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-20220161246-A1 | NITROGEN HETEROCYCLIC CARBENE LIGANDS AND RUTHENIUM CATALYSTS THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Paimai New Materials (chengdu) Co., Ltd. (CN) | 2022-05-26 | — | — | US | disclosed |
| WO-2020140441-A1 | NITROGEN HETEROCYCLIC CARBENE LIGANDS AND RUTHENIUM CATALYSTS THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 成都开美思商务信息咨询中心(有限合伙) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020140441-A1 | NITROGEN HETEROCYCLIC CARBENE LIGANDS AND RUTHENIUM CATALYSTS THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 成都开美思商务信息咨询中心(有限合伙) | 2020-07-09 | — | — | WO | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| CN-110041262-B | Nitrogen heterocyclic carbene ligand and ruthenium catalyst, preparation method and application thereof | 成都开美思商务信息咨询中心(有限合伙) | 2020-03-27 | — | — | CN | disclosed |
| WO-1995030652-A1 | SUBSTITUTED SPIRODIENES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995021817-A1 | SUBSTITUTED SPIRO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5393790-A | Diphenyl- or phenyl/pyridyl-substituted spiroheptenes, -octenes,-nonenes or -decenes; cyclooxygenase II inhibitors; side effect reduction; antipyretics; antiarthritic agents | G.D. SEARLE & CO. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0269109-B1 | PROCESS FOR THE PREPARATION OF DIALKYL 2-VINYLCYCLOPROPANE-1,1-DICARBOXYLATES | HENKEL CORPORATION (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0270006-B1 | EFFICIENT CIS-TO-TRANS ISOMERIZATION OF 1, 4-DIHALOBUTENE-2 | HENKEL CORPORATION (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0339669-A1 | Process for preparing indole-3-carboxylic acid esters of trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4781807-A | HYDROGEN BROMIDE CATALYST | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0270006-A1 | Efficient cis-to-trans isomerization of 1, 4-dihalobutene-2 | HENKEL CORPORATION (US) | 1988-06-08 | — | — | EP | disclosed |
| EP-0269109-A2 | Process for the preparation of dialkyl 2-vinylcyclopropane-1,1-dicarboxylates | HENKEL CORPORATION (US) | 1988-06-01 | — | — | EP | disclosed |
| US-4713479-A | Synthesis of high-purity dialkyl 2-vinylcyclopropane-1,1-dicarboxylate | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220161246-A1 | NITROGEN HETEROCYCLIC CARBENE LIGANDS AND RUTHENIUM CATALYSTS THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE2, WEE1, FARSB | NPSR1 1989/4885MEN1 1286/4885KMT2A 4462/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | NPSR1 177/4885MEN1 4038/4885KMT2A 2469/4885 |
| US-12023661-B2 | Nitrogen heterocyclic carbene ligands and ruthenium catalysts thereof, preparation method therefor and application thereof | WEE2, WEE1, FARSB | NPSR1 1989/4885MEN1 1286/4885KMT2A 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.